Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026

Rhea-AI Summary

Cereno Scientific (Nasdaq First North: B) will attend JPM Week 2026 in San Francisco and participate at the Biotech Showcase from January 12–18, 2026, with Biotech Showcase sessions running January 12–14, 2026.

The company said it will hold investor and partner meetings throughout the week to discuss progress across its HDAC inhibitor portfolio, including advancement of lead candidate CS1 toward a global Phase IIb trial in PAH and Phase I data supporting CS014 moving into Phase II. Investors can request meetings via the Biotech Showcase partnering platform or by emailing business.development@cerenoscientific.com. For IR contact, use tove.bergenholt@cerenoscientific.com or phone +46 73-236 62 46.

Key Figures

JPM Week dates January 12–18, 2026 Attendance window in San Francisco

Biotech Showcase dates January 12–14, 2026 Investor and partnering event during JPM Week

Market Reality Check

$43.15 Last Close

Volume Relative volume at 0.87x 20-day average (15,609,813 vs 17,992,629) shows typical activity. normal

Technical Price 43.15 is trading above the 200-day MA at 32.46, reflecting a sustained uptrend.

Peers on Argus

Gold peers WPM, FNV, AU, AEM, and KGC show gains between 3.04% and 4.56%, broadly aligning with B’s 3.33% move and pointing to sector-wide strength.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Drug access update	Positive	+2.2%	Leqembi added to China Commercial Insurance Innovative Drug List from <b>Jan 1, 2026</b>.
Dec 08	Trial clearance	Positive	+2.2%	U.S. FDA cleared global Phase IIb trial of CS1 for PAH.
Dec 03	Product launch	Positive	-1.3%	Launch of ETQ Reliance Go EQMS for small- and mid-sized manufacturers.
Dec 02	Asset divestiture	Neutral	-3.1%	Completed sale of Tongon mine and properties for consideration up to <b>$305M</b>.
Dec 01	IPO evaluation	Positive	+2.4%	Board authorized exploration of IPO for North American gold assets subsidiary.

Pattern Detected

News has typically led to modest single-digit moves, with mostly aligned reactions and one recent divergence on a product launch.

Recent Company History

Over recent months, the company’s news flow has mixed strategic portfolio actions with partner-driven product milestones. A potential IPO of North American gold assets and the Tongon divestiture signaled active portfolio management. At the same time, partner Eisai advanced Leqembi’s access in China, while ETQ launched a new EQMS product. These events generally produced moderate single-day moves, mostly in the low single digits, suggesting that even material updates have translated into relatively contained price reactions.

Market Pulse Summary

This announcement highlights planned participation in JPM Week and the Biotech Showcase from January 12–18, 2026, signaling a focus on investor outreach and partnering discussions. It underscores progress in an HDAC inhibitor portfolio, including advancing CS1 toward Phase IIb and CS014 toward Phase II. Investors may track how this visibility complements recent strategic and regulatory milestones, and watch for future updates on clinical timelines, collaborations, or capital plans emerging from these meetings.

Key Terms

hdac inhibitor medical

"progress across our pioneering HDAC inhibitor portfolio."

A HDAC inhibitor is a drug that blocks enzymes (histone deacetylases) which act like dimmer switches on genes, changing how tightly DNA is packaged and thereby turning certain genes up or down. For investors, these drugs matter because they can alter disease pathways—particularly in cancer and some neurological conditions—so clinical trial results, safety profiles, and regulatory decisions directly affect a company’s drug value and market potential.

phase IIb medical

"advancement of our lead candidate CS1 toward a global Phase IIb trial in PAH"

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

phase I medical

"the strong Phase I data supporting CS014's progression"

A Phase I clinical trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety and finding an appropriate dose by studying a small group of volunteers or patients. Investors watch Phase I results because they reveal early signs of safety, tolerability and how the body handles the treatment—information that helps gauge development risk and the likelihood and timing of later, larger trials that drive a drug’s value, much like a test drive reveals whether a prototype is worth further investment.

phase II medical

"supporting CS014's progression into Phase II has already generated"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

pulmonary arterial hypertension medical

"global Phase IIb trial in PAH and the strong Phase I data"

Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.

AI-generated analysis. Not financial advice.

GOTHENBURG, Sweden, Dec. 12, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will attend JPM Week 2026 and participate at the Biotech Showcase in San Fransisco, US, on January 12-18, 2026

The JPM Week is the largest annual gathering for global life science stakeholders, bringing together biotechnology and pharmaceutical companies, investors, analysts, patient advocacy groups, and industry experts. In parallel with the main J.P. Morgan Healthcare Conference, a broad set of satellite events, partner meetings, and scientific and corporate presentations take place across the city, creating a hub for strategic dialogue, collaboration, and innovation.

Cereno Scientific will participate in meetings throughout the week and will also be present at the Biotech Showcase, an investor and partnering event, on January 12-14, running concurrently with J.P. Morgan's conference activities.

"Our participation in JPM Week marks an important moment each year as we engage with the global biotech and pharma community at one of the industry's most influential gatherings," said Sten R. Sörensen, CEO of Cereno Scientific. "Over the past year, we have achieved meaningful progress across our pioneering HDAC inhibitor portfolio. Sharing this momentum, including the advancement of our lead candidate CS1 toward a global Phase IIb trial in PAH and the strong Phase I data supporting CS014's progression into Phase II has already generated increasing interest from potential partners, investors, and scientific leaders. We look forward to a highly productive week of discussions as we continue to build strategic relationships and explore opportunities that support our mission to bring disease-modifying treatments to patients with rare cardiovascular and pulmonary diseases." 

To book a meeting with Cereno Scientific, please contact: business.development@cerenoscientific.com, or connect with the team via the Biotech Showcase partnering platform.

For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email:  tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling, improvement of right heart function and enhanced patient quality of life in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cereno-scientific/r/cereno-scientific-to-attend-jpm-week-and-biotech-showcase-in-san-francisco--us--on-january-12-18--20,c4280621

The following files are available for download:

https://mb.cision.com/Main/14131/4280621/3838858.pdf

Press release

 

View original content:https://www.prnewswire.com/news-releases/cereno-scientific-to-attend-jpm-week-and-biotech-showcase-in-san-francisco-us-on-january-12-18-2026-302639988.html

SOURCE Cereno Scientific

FAQ

When will Cereno Scientific (B) attend JPM Week 2026 and the Biotech Showcase?

Cereno Scientific will attend JPM Week January 12–18, 2026 and the Biotech Showcase on January 12–14, 2026.

How can investors book a meeting with Cereno Scientific (B) during JPM Week 2026?

Investors can request meetings via the Biotech Showcase partnering platform or email business.development@cerenoscientific.com.

What program updates will Cereno Scientific (B) discuss at JPM Week 2026?

The company plans to discuss its HDAC inhibitor portfolio, including CS1's progression toward a global Phase IIb trial in PAH and Phase I data supporting CS014 moving into Phase II.

Who is the investor relations contact for Cereno Scientific (B) for JPM Week 2026?

Investor relations contact is Tove Bergenholt at tove.bergenholt@cerenoscientific.com or phone +46 73-236 62 46.

Will Cereno Scientific (B) hold partnering meetings at Biotech Showcase 2026?

Yes, the company will participate in partnering meetings during the Biotech Showcase (January 12–14, 2026).